Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 25Lymphoma, Mantle-Cell 16Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Non-Hodgkin 5Lymphoma 5Lymphoma, B-Cell, Marginal Zone 4Lymphoma, Follicular 3Leukemia, B-Cell 3Waldenstrom Macroglobulinemia 2Lymphoma, B-Cell 2Leukemia 2Cardiovascular Diseases 2Pyloric Stenosis, Hypertrophic 1Neuritis 1Neoplasm, Residual 1Lymphoproliferative Disorders 1Hematologic Neoplasms 1Anemia, Hemolytic, Autoimmune 1

Interventions

Rituximab 5fludarabine 4Tacrolimus 4Epoetin Alfa 4Cyclophosphamide 4Busulfan 4Darbepoetin alfa 3Alemtuzumab 3fludarabine phosphate 2entrectinib 2atezolizumab 2alectinib 2Thiotepa 2Therapeutics 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Methotrexate 2Etoposide 2Early Intervention, Educational 2Cytarabine 2Bortezomib 2Antilymphocyte Serum 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2venetoclax 1trametinib 1tirbanibulin 1sargramostim 1plerixafor 1phenethyl isothiocyanate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoproliferative Disorders × acalabrutinib × Clear all
NCT04883437 2026-02-09

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Emory University

Phase 2 Recruiting
49 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoproliferative Disorders, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡